Shattuck Labs stock price target maintained at $18 by Raymond James

Raymond James has retained its strong buy rating and price target of $18.00 for Shattuck Labs (NASDAQ:STTK) shares, despite the stock's recent decline of nearly 10% over the past week. The company's shares have delivered a remarkable 152% return over the past year, and Shattuck Labs reported solid third-quarter 2026 financial results with more cash than debt on its balance sheet.

Analysts anticipate a Phase 2 study for SL-325 in Crohn's disease and a planned Phase 2 study for hidradenitis suppurativa to begin in the fourth quarter of 2026. Shattuck Labs also initiated preclinical trials for SL-846, a DR3 x IL-23R bispecific, with initial Phase 1 data expected in 2027. Analysts highlight Shattuck Labs' potential in the pharmaceutical market, with several firms updating their coverage and price targets for the company's shares.